Abstract
α-Helical membrane proteins (MPs) are the targets for many pharmaceutical drugs and play important roles in human physiology. In recent years, significant progress has been made in determining their atomic structure using X-ray crystallography. However, a major bottleneck in MP crystallography still remains, namely, the identification of conditions that give crystals that are suitable for structural determination. In 2008, we undertook an analysis of the crystallization conditions for 121 α-helical MPs to design a rationalized sparse matrix crystallization screen, MemGold. We now report an updated analysis that includes a further 133 conditions. The results reveal the current trends in α-helical MP crystallization with notable differences since 2008. The updated information has been used to design new crystallization and additive screens that should prove useful for both initial crystallization scouting and subsequent crystal optimization.
Keywords: membrane proteins, crystallization, crystallization additives
Introduction
Substantial progress has been made in tackling many of the hurdles faced in determining the crystal structures of α-helical membrane proteins (MPs),1 including their production using recombinant systems,2, 3 methods for engineering and screening stability,4, 5 and in X-ray data collection using microfocus beamlines.6, 7 However, growing well-ordered three-dimensional crystals still represents a significant challenge that must be overcome. In 2008, we suggested the use of a rationalized sparse matrix type MP crystallization screen based on the crystallization conditions for 121 α-helical MPs deposited in the PDB at that time.8 Since our first analysis, however, the number of structures has more than doubled (see http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html). In response to this increase in available crystallization data, an updated analysis is now presented that includes a total of 254 crystallization conditions from unique α-helical MP structures. Here, we present the summary of this analysis and show that the initial trends described in 2008 are broadly holding, but reveal intriguing new developments such as an increase in the number of cases where additional or mixed detergents have been required for structural determination. In addition to our analysis of crystallization conditions and the presentation of a complimentary crystal screen MemGold 2™, an in-depth analysis of additives has also been possible with the increased database. The use of additional chemicals to optimize initial crystals to improve diffraction quality is well documented and many commercial kits are available.9, 10 However, an additive screen targeted specifically for MPs has so far remained absent. A specific MP additive screen is therefore suggested to facilitate crystal optimization. As research groups start to tackle the more challenging eukaryotic MPs, we anticipate that these updated screens should enable more rational and successful approaches to crystallization and subsequent structural determination.
Results
Current trends in the number and types of α-helical MP crystal structures
Since 2008 an additional 133 novel α-helical MP structures have been added to our original crystallization database, bringing the total entries to 254. As before, these have been grouped into eight different families broadly divided by function (Fig. 1, inset). The data clearly show an increase in the determination of channel and transporter structures, with a concomitant decrease for the respiratory complexes. The number of additional structures for both the channel and transporter families has increased by 45 and 43, respectively, now making these two families the largest in the database, accounting for more than half of all the structures (alpha-MP-database-2012.xlsx). In 2008, respiratory complex structures accounted for 24% of the total; this has now dropped to 14%, signifying the addition of only seven new structures since this time. Another change has been the increase in the G-protein-coupled receptor (GPCR) family, which now makes up 7% of the database with 18 structures, up from 4% (or five structures) in 2008. Significant progress has been made in the structural determination of GPCRs due to a number of technological advancements in protein engineering and lipidic mesophase crystallization.11–13 The contribution from the photosynthetic and light-harvesting complexes has also reduced, decreasing from 12 to 7%, with only three new structures. ATPases have increased from five structures in 2008 to 16, and now account for 6%, which is similar to the “others” category that includes α-helical MPs that could not be divided into the seven larger families described above.
Figure 1.
Successful detergents used for α-helical membrane protein crystallization. Numbers for each detergent class are shown, subdivided into the eight MP families used in the analysis. Respiratory complexes (brown), channels (black), transporters (green), photosynthetic and light-harvesting complexes (purple), GPCRs (red), ATPases (orange), bacterial rhodopsins (blue), and the “others” category (olive), those not fitting the seven main groupings. This color scheme is used throughout. Inset: Pie charts showing the change in the proportion of structures belonging to the eight MP families between 2008 and 2012, and the percentage contribution made by each family to the respective analyses is indicated.
Successful detergents
The majority of MP structures deposited in the Protein Data Bank have been determined using crystals grown from detergent-solubilized protein using traditional vapor diffusion experiments. In these experiments, the sample being crystallized is a mixture of both protein and associated detergent, making detergent selection a critical parameter for growing well-ordered, well-diffracting crystals.14 Significant progress has recently been made in the development of novel detergents for use in MP purification and crystallization.15, 16 However, as in 2008, the alkyl maltopyranosides account for the majority of successfully used detergents, accounting for half of all structures in the database (Fig. 1) followed by the alkyl glucopyranosides (25%), amine oxides (7%), and polyoxyethylene glycols (7%). A full breakdown of individual detergents is given in Supporting Information Figure S1. Transporters still account for the majority of structures determined using alkyl maltopyranosides with 50 entries, followed by channels with 40. The most successful alkyl maltopyranoside detergent is n-dodecyl-β-d-maltopyranoside (DDM), which accounts for 22 transporter and 17 channel structures followed by n-decyl-β-d-maltopyranoside (DM), accounting for 13 transporter and 16 channel structures, respectively.
The choice of detergent depends on many different parameters, including solubilization efficiency, protein stability, and retention of function, such that some researchers may in practice have little “choice” at all! Nevertheless, considerable effort should be made to screen for crystals in shorter chain detergents as there is a greater probability of obtaining crystals that diffract to a higher resolution.17 An updated analysis of the resolution obtained here in the eight largest detergent classes further supports this conclusion [Fig. 2(A)], with the alkyl glucopyranoside detergent, n-octyl-β-d-glucopyranoside (OG), having both the highest resolution structure at 1.15 Å that of a yeast aquaporin Aqy118 and highest mean resolution at 2.4 Å. The amine oxides, including n-lauryl dimethylamine-N-oxide (LDAO), gave the next most favorable resolution statistics followed by n-nonyl-β-d-glucopyranoside, both with mean resolutions of 2.7 Å. There is unlikely to ever be a single panacean detergent that can be applied to all types of MPs. Nevertheless, the data support the continued use of DDM, DM, OG, and LDAO as good first-choice detergents when screening crystallization conditions using vapor diffusion methods.
Figure 2.
Analysis of reported resolution for α-helical membrane proteins. A: Box plots displaying the structural resolution for seven of the most successful crystallization detergent classes; the middle line in each box represents the mean value for each detergent class. Only structures crystallized using a single detergent were included. In red, the same analysis was used for all structures determined using lipidic phase methods. B: Reported high-resolution limit for the eight MP families analyzed in the study.
Of course, a rational and intelligent approach should always be taken into account for detergent screening of MPs, which can now be accomplished easily using fluorescent-based methods early on in the structural determination process.19, 20 A notable change since 2008 has been the increased success of detergent mixtures in the reported crystallization conditions. Interestingly, all families except the bacterial rhodopsins had at least one example where >1 detergent has been reported, suggesting that this should be a common approach to adopt early on in the screening process. However, no trend yet exists that may hint at whether certain detergent classes may be paired more successfully.
An important technical development in MP crystallization since our last analysis has been the increased use of lipidic phases, either in cubic phase,21 sponge phase22 or in the use bicelles.23 As highlighted in Figure 2(A), the mean resolution for structures determined using these methods is 2.5 Å, almost half an ångström lower than for the alkyl maltopyranoside detergents and very close to the mean resolution obtained for OG, which in many cases is too “harsh” for α-helical MPs. These data add further support to the early adoption of lipidic phase crystallization in MP structure projects.
Precipitants, buffers, salts, and pH
Our analysis in 2008 of precipitants revealed a striking success for small MW PEGs in the crystallization of channels and transporters, with larger MW PEGs being more successful for respiratory complexes and MPs with large hydrophilic domains.8 These trends have remained in the updated dataset, with the notable appearance of small MW PEGs in the crystallization of the eukaryotic GPCR family (Fig. 3). The successful concentration ranges have also been maintained, with small MW PEGs being successful at concentrations between 20 and 40% and with larger MW PEGs being used at lower concentrations between 5 and 20% (Fig. 3, inset). However, the successful use of organic molecules such as MPD is still low, further confirming their unsuitability as general crystallization reagents for α-helical MPs; a situation that is dramatically different for outer MPs where organic molecules are clearly more successful.24
Figure 3.
Analysis of precipitants. The different precipitants used in the successful crystallization of the eight MP families are shown. Salts, which include ammonium sulfate, sodium chloride, lithium sulfate, sodium phosphate, and trisodium citrate (green), and the organic molecule (±)-2-methyl-2,4-pentanediol (MPD) (purple) are indicated. The polyethylene glycols and other polymers that include Jeffamine and pentaerythritol propoxylate (5/4 PO/OH) are grouped into three classes depending on size, small MW (blue), medium MW (red), and large MW (yellow). Inset: The concentration of PEGs reported in the database are shown, revealing a broadly similar pattern to 2008.
Buffering chemicals and salts often have a significant impact on protein crystallization; in particular polyvalent cations and anions are often essential for crystallization.25, 26 Our data reveal a broadly similar pattern to 2008 (Supporting Information Fig. S1), with no clear correlation between different buffer types and MP family. Of note in the present data is that 37 different salts have been reported, covering many of the commonly found polyvalent cations and anions. The broad pH distribution in the conditions was also of interest, particularly for channels, with structures reported at pH values between 3.5 and 10 (Supporting Information Fig. S2). Screening over a wide range of pH values is therefore recommended to efficiently cover crystallization space.
Additives
For many projects, an initial crystal condition will require optimization often by the addition of small molecules, salts, and specific ligands. Figure 4 shows the range of different small molecules and salt additives that have been reported to improve initial crystallization conditions for α-helical MPs in the present literature. Of note is that all families are represented, suggesting that the use of additional crystallization additives is generally applicable and should be routinely explored. As observed previously, multivalent salts and polyalcohols appear prominently in the database, accounting for 10 and 15%, respectively. However, a notable difference is a substantial increase in the number of secondary detergents and nonvolatile organic molecules that are now being recorded, which account for 19 and 12%, respectively, up from 10 and >1% in 2008. Structures of membrane transporters account for much of this increase, suggesting that screening secondary detergents for members of this family would be especially worthwhile. This observation supports the data presented in Figure 1, which shows the increased use of detergent mixtures for crystallization. Interestingly, the reported use of additional lipids as additives appears to be mainly isolated to channels, with monovalent salts being more successful for transporters.
Figure 4.
Successful additives used for crystallization. The range of additives used for successful crystallizations are shown for each MP family. The additives have been grouped into more general classes for clarity and colored according to Figure 1.
Discussion
Recent advances in the use of crystallization robotics have substantially increased the number of different crystallization conditions that can be screened. A common conundrum for structural biologists is how many conditions are enough to adequately cover “crystallization space” for a given MP sample? This question is especially pertinent for eukaryotic MPs when amounts are likely to be far scarcer when compared with their prokaryotic counterparts. Many of the MPs analyzed in this study crystallized in similar precipitant conditions, with approximately two-thirds being crystallized in a low MW PEG. However, the pH, salt, and buffer components of the crystallization conditions differed substantially, suggesting that successful crystallization screens should be more varied in these parameters rather than the precipitant type. Based on these data, a new sparse matrix style screen MemGold 2 is presented (Supporting Information Table S1). Our analysis of the available crystallization data suggests that MemGold and MemGold 2 provide a comprehensive set of initial screening conditions for α-helical MP crystallization.
Additionally, analysis of these data clearly shows that exploring the use of smaller micelle detergents, in many cases as additives, should be carried out as an avenue to improve diffraction quality following initial crystallization success. As in detergent selection, no single additive is likely to emerge as a panacea for optimization. Nevertheless, optimization is still likely to be required and to facilitate the identification of successful additives, we have designed a novel set of chemicals from the database into a 96-format screen, MemAdvantage, for implementation in robotic screening pipelines (Table I). We anticipate that this screen will prove valuable during crystal optimization and combined with the present analysis and databases provide a useful resource for the MP structure community.
Table I.
MemAdvantage: A Targeted Additive Screen for α-Helical Membrane Protien Crystal Optimization
Additive | Classification | Suggested crystal drop concentration | |
---|---|---|---|
1 | 10% (w/v) 1,2,3-Heptanetriol | Amphiphile | 1.0% |
2 | 20% (w/v) Benzamidine hydrochloride hydrate | Amphiphile | 2.0% |
3 | 40% (w/v) Sucrose | Carbohydrate | 4.0% |
4 | 30% (w/v) Trehalose | Carbohydrate | 3.0% |
5 | 0.1M EDTA | Chelating agent | 0.01M |
6 | 0.1M EGTA | Chelating agent | 0.01M |
7 | 30% (w/v) Butylated hydroxytoluene | Small molecule | 3.0% |
8 | 0.1M C-HEGA-11 | Detergent | 0.01M |
9 | 0.009M C12E8 | Detergent | 0.1 mM |
10 | 0.08M C8E4 | Detergent | 8.0 mM |
11 | 0.08M CHAPS | Detergent | 8.0 mM |
12 | 3M CYMAL 1 | Detergent | 0.3M |
13 | 1.2M CYMAL 2 | Detergent | 0.12M |
14 | 0.08M CYMAL 4 | Detergent | 8.0 mM |
15 | 0.05M CYMAL 5 | Detergent | 5.0 mM |
16 | 0.005M CYMAL 6 | Detergent | 0.5 mM |
17 | 0.002M CYMAL 7 | Detergent | 0.2 mM |
18 | 0.002Mn-Dodecyl- β-d-maltopyranoside | Detergent | 0.2 mM |
19 | 0.025Mn-Decanoyl sucrose | Detergent | 0.25 mM |
20 | 0.014M Deoxy-Big CHAP | Detergent | 1.4 mM |
21 | 0.018Mn-Decyl-β-d-maltopyranoside | Detergent | 1.8 mM |
22 | 0.0036M Decyl maltose neopentyl glycol | Detergent | 0.036 mM |
23 | 0.003M Dodecanoyl sucrose | Detergent | 0.3 mM |
24 | 0.015M FOS-Choline-12 | Detergent | 1.5 mM |
25 | 0.395M FOS-Choline-9 | Detergent | 39.5 mM |
26 | 0.014M HEGA 11 | Detergent | 1.4 mM |
27 | 0.014M HEGA 10 | Detergent | 7.0 mM |
28 | 0.012Mn-Dodecyl-N,N-dimethylamine-N-oxide | Detergent | 1.2 mM |
29 | 0.001M Lauryl maltose neopentyl glycol | Detergent | 0.01 mM |
30 | 20% (v/v) MERPOL HCS | Detergent | 2.0% |
31 | 0.015Mn-Dodecyl-N,N-dimethylglycine | Detergent | 1.5 mM |
32 | 0.065Mn-Nonyl-β-d-glucopyranoside | Detergent | 6.5 mM |
33 | 0.06Mn-Nonyl-β-d-maltopyranoside | Detergent | 6.0 mM |
34 | 0.2Mn-Octyl-β-d-glucopyranoside | Detergent | 20.0 mM |
35 | 0.01MN-Octyl-β-d-maltopyranoside-fluorinated (OM-F) | Detergent | 1.0 mM |
36 | 0.01M Octyl glucose neopentyl glycol | Detergent | 1.0 mM |
37 | 0.003Mn-Tridecyl-β-d-maltopyranoside | Detergent | 0.03 mM |
38 | 0.015M 3-Dodecylamido-N-N′-dimethylpropyl amine oxide | Detergent | 1.5 mM |
39 | 0.045M [(3-(3 Butyl-3-phenylheptanamido)-N, N-dimethylpropan-1-amine oxide)] | Detergent | 4.5 mM |
40 | 0.0059Mn-Undecyl-β-d-maltopyranoside | Detergent | 0.59 mM |
41 | 0.002Mn-Undecyl-β-d-thiomaltopyranoside | Detergent | 0.2 mM |
42 | 0.006M Anzergent 3-12 | Detergent | 0.6 mM |
43 | 0.7Mn-Heptyl-β-d-glucopyranoside | Detergent | 70 mM |
44 | Deuterium oxide | Heavy water | — |
45 | 0.3M Glycyl-glycyl-glycine | Linker | 30.0 mM |
46 | 0.1M Lithium citrate | Monovalent | 10 mM |
47 | 0.1M Lithium sulfate | Monovalent | 10 mM |
48 | 0.1M Potassium chloride | Monovalent | 10 mM |
49 | 0.1M Potassium fluoride | Monovalent | 10 mM |
50 | 0.1M Potassium silicate | Monovalent | 10 mM |
51 | 0.1M Rubidium chloride | Monovalent | 10 mM |
52 | 0.1M Sodium azide | Monovalent | 10 mM |
53 | 0.1M Sodium chloride | Monovalent | 10 mM |
54 | 0.1M Sodium fluoride | Monovalent | 10 mM |
55 | 0.1M Sodium phosphate | Monovalent | 10 mM |
56 | 0.1M Sodium silicate acetate | Monovalent | 10 mM |
57 | 0.1M Ammonium citrate | Multivalent | 10 mM |
58 | 0.1M Ammonium sulfate | Multivalent | 10 mM |
59 | 0.1M Cadmium chloride | Multivalent | 10 mM |
60 | 0.1M Calcium chloride | Multivalent | 10 mM |
61 | 0.1M Chromium chloride | Multivalent | 10 mM |
62 | 0.1M Cobalt chloride | Multivalent | 10 mM |
63 | 0.1M Copper chloride | Multivalent | 10 mM |
64 | 0.1M Gadolinium chloride | Multivalent | 10 mM |
65 | 0.1M Magnesium chloride | Multivalent | 10 mM |
66 | 0.1M magnesium sulfate | Multivalent | 10 mM |
67 | 0.1M Manganese chloride | Multivalent | 10 mM |
68 | 0.1M Osmium chloride | Multivalent | 10 mM |
69 | 0.1M Samarium chloride | Multivalent | 10 mM |
70 | 0.1M Strontium chloride | Multivalent | 10 mM |
71 | 0.1M Zinc nitrate | Multivalent | 10 mM |
72 | 0.1M Zinc sulfate | Multivalent | 10 mM |
73 | 30% (w/v) 1,6-Hexanediol | Organic, nonvolatile | 3.0% |
74 | 30% (w/v) 2-Methyl-2,4-pentanediol | Organic, nonvolatile | 3.0% |
75 | 30% (v/v) Dimethyl sulfoxide | Organic, nonvolatile | 3.0% |
76 | 0.08M Foscarnet | Organic, nonvolatile | 8 mM |
77 | 30% (w/v) Sodium phosphonoformate tribasic hexahydrate | Organic, nonvolatile | 3.0% |
78 | Glutaric acid pH 6.0 | Organic, nonvolatile | 100 mM |
79 | 0.01ML-Glutathione reduced | Reducing agent | 1.0 mM |
80 | 50% (v/v) PEG 400 | Organic, nonvolatile | 5.0% |
81 | 5% (w/v) Polyvinylpyrrolidone K15 | Organic, nonvolatile | 0.5% |
82 | 0.1M Spermidine | Polyamine | 10 mM |
83 | 50% (v/v) Jeffamine M-600 | Organic, nonvolatile | 5.0% |
84 | 0.1M Taurine | Linker | 10 mM |
85 | 40% (v/v) 1,3-Propanediol | Organic, volatile | 4.0% |
86 | 40% (v/v) 1,3 Butanediol | Organic, volatile | 4.0% |
87 | 40% (v/v) tert-Butanol | Organic, volatile | 4.0% |
88 | 30% (v/v) Ethanol | Organic, volatile | 3.0% |
89 | 30% (v/v) Isopropanol | Organic, volatile | 3.0% |
90 | 10% (v/v) 1,2-Butandiol | Organic, volatile | 1.0% |
91 | 0.1M Triethylammonium phosphate | Organic, volatile | 10 mM |
92 | 30% (v/v) Ethylene glycol | Polyalcohol | 3.0% |
93 | 30% (v/v) Glycerol | Polyalcohol | 3.0% |
94 | 0.05M 2-Mercaptoethanol | Reducing agent | 5.0 mM |
95 | 0.05M DTT | Reducing agent | 5.0 mM |
96 | 0.05M TCEP hydrochloride | Reducing agent | 10 mM |
Materials and Methods
An analysis of the deposited structures for α-helical MPs was carried out as described previously.8 The original database (alpha-MP-database.xls) constructed in 2008 was complemented with additional unique α-helical MP structures to create the updated database (alpha-MP-database-2012.xlsx). Conditions from proteins crystallized using both vapor diffusion and lipidic mesophase crystallization are now included in the database and analysis. To avoid biasing the analysis, conditions from the same MP were excluded if they were identical. Reported conditions for each PDB entry were then divided into the different crystallization components: precipitant, buffer, pH, salts, additives, and detergents along with their respective concentrations. Chemicals were considered additives if their concentration was less than 20 mM, for example, zinc sulfate at 5 mM was counted as an additive and not as a salt unless otherwise indicated as such in the PDB deposition or associated publication. These data were then analyzed by constructing a series of stacked bar charts showing the number of successful crystallizations for each α-helical MP family against the individual chemicals for each component of the crystallization experiments.
The MemGold 2 and MemAdvantage screens were designed by selecting 96 nonredundant conditions from this database. Concentrations suggested are guidelines and may be varied when preparing custom screens based on these reagents. However, both screens are currently commercially available through Molecular Dimensions Ltd. (UK).
Glossary
Abbreviations
- Big CHAP
N,N′-bis-(3-d-gluconamidopropyl)deoxycholamide
- CHAPS
3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate/N,N-dimethyl-3-sulfo-N-[3-[[3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]propyl]-1-propanaminium hydroxide
- C12E8
polyoxyethylene(8)dodecyl ether
- CYMAL
cyclohexyl-β-d-maltopyranoside
- DDM
n-dodecyl-β-d-maltopyranoside
- DHPC
1,2-diheptanoyl-sn-glycero-3-phosphocholine
- DM
n-decyl-β-d-maltopyranoside
- FOS-Choline
phosphocholine
- HEGA
N-hydroxyethylglucamide
- LDAO
lauryldimethylamine-N-oxide
- MEGA
N-methylglucamide
- MPD
(±)-2-methyl-2,4-pentanediol
- OG
n-octyl-β-d-glucopyranoside
Supplementary material
Additional Supporting Information may be found in the online version of this article.
References
- 1.Bill RM, Henderson PJF, Iwata S, Kunji ERS, Michel H, Neutze R, Newstead S, Poolman B, Tate CG, Vogel H. Overcoming barriers to membrane protein structure determination. Nat Biotechnol. 2011;29:335–340. doi: 10.1038/nbt.1833. [DOI] [PubMed] [Google Scholar]
- 2.Tate CG, Haase J, Baker C, Boorsma M, Magnani F, Vallis Y, Williams DC. Comparison of seven different heterologous protein expression systems for the production of the serotonin transporter. Biochim Biophys Acta. 2003;1610:141–153. doi: 10.1016/s0005-2736(02)00719-8. [DOI] [PubMed] [Google Scholar]
- 3.Chaudhary S, Pak JE, Gruswitz F, Sharma V, Stroud RM. Overexpressing human membrane proteins in stably transfected and clonal human embryonic kidney 293S cells. Nat Protoc. 2012;7:453–466. doi: 10.1038/nprot.2011.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Zhou Y, Bowie JU. Building a thermostable membrane protein. J Biol Chem. 2000;275:6975–6979. doi: 10.1074/jbc.275.10.6975. [DOI] [PubMed] [Google Scholar]
- 5.Sonoda Y, Newstead S, Hu N-J, Alguel Y, Nji E, Beis K, Yashiro S, Lee C, Leung J, Cameron AD, Byrne B, Iwata S, Drew D. Benchmarking membrane protein detergent stability for improving throughput of high-resolution X-ray structures. Structure. 2011;19:17–25. doi: 10.1016/j.str.2010.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Evans G, Axford D, Waterman D, Owen RL. Macromolecular microcrystallography. Crystallogr Rev. 2011;17:105–142. [Google Scholar]
- 7.Bowler MW, Guijarro M, Petitdemange S, Baker I, Svensson O, Burghammer M, Mueller-Dieckmann C, Gordon EJ, Flot D, McSweeney SM, Leonard GA. Diffraction cartography: applying microbeams to macromolecular crystallography sample evaluation and data collection. Acta Crystallogr D Biol Crystallogr. 2010;66:855–864. doi: 10.1107/S0907444910019591. [DOI] [PubMed] [Google Scholar]
- 8.Newstead S, Ferrandon S, Iwata S. Rationalizing α-helical membrane protein crystallization. Protein Sci. 2008;17:466–472. doi: 10.1110/ps.073263108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Cudney R, Patel S, Weisgraber K, Newhouse Y, McPherson A. Screening and optimization strategies for macromolecular crystal growth. Acta Crystallogr D Biol Crystallogr. 1994;50:414–423. doi: 10.1107/S0907444994002660. [DOI] [PubMed] [Google Scholar]
- 10.Chayen NE, Saridakis E. Protein crystallization: from purified protein to diffraction-quality crystal. Nat Methods. 2008;5:147–153. doi: 10.1038/nmeth.f.203. [DOI] [PubMed] [Google Scholar]
- 11.Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Sci Signal. 2010;330:1066. doi: 10.1126/science.1194396. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Chien EYT, Liu W, Zhao Q, Katritch V, Won Han G, Hanson MA, Shi L, Newman AH, Javitch JA, Cherezov V, Stevens RC. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Sci Signal. 2010;330:1091. doi: 10.1126/science.1197410. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, Abagyan R, Cherezov V, Liu W, Han GW, Kobayashi T, Stevens RC, Iwata S. Structure of the human histamine H1 receptor complex with doxepin. Nature. 2011;475:65–70. doi: 10.1038/nature10236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Iwata S. Methods and Results in Crystallization of Membrane Proteins. La Jolla, CA, USA: International University Line; 2003. [Google Scholar]
- 15.Zhang Q, Tao H, Hong W-X. New amphiphiles for membrane protein structural biology. Methods. 2011;55:318–323. doi: 10.1016/j.ymeth.2011.09.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Chae PS, Rasmussen SGF, Rana RR, Gotfryd K, Chandra R, Goren MA, Kruse AC, Nurva S, Loland CJ, Pierre Y, Drew D, Popot J-L, Picot D, Fox BG, Guan L, Gether U, Byrne B, Kobilka B, Gellman SH. Maltose neopentyl glycol (MNG) amphiphiles for solubilization, stabilization and crystallization of membrane proteins. Nat Methods. 2010;7:1003–1008. doi: 10.1038/nmeth.1526. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Sonoda Y, Cameron A, Newstead S, Omote H, Moriyama Y, Kasahara M, Iwata S, Drew D. Tricks of the trade used to accelerate high-resolution structure determination of membrane proteins. FEBS Lett. 2010;584:2539–2547. doi: 10.1016/j.febslet.2010.04.015. [DOI] [PubMed] [Google Scholar]
- 18.Fischer G, Kosinska-Eriksson U. Crystal structure of a yeast aquaporin at 1.15 Å reveals a novel gating mechanism. PLoS Biol. 2009;7:e1000130. doi: 10.1371/journal.pbio.1000130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Kawate T, Gouaux E. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure. 2006;14:673–681. doi: 10.1016/j.str.2006.01.013. [DOI] [PubMed] [Google Scholar]
- 20.Newstead S, Kim H, Heijne Von G, Iwata S, Drew D. High-throughput fluorescent-based optimization of eukaryotic membrane protein overexpression and purification in Saccharomyces cerevisiae. Proc Natl Acad Sci USA. 2007;104:13936–13941. doi: 10.1073/pnas.0704546104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Cherezov V. Lipidic cubic phase technologies for membrane protein structural studies. Curr Opin Struct Biol. 2011;21:559–566. doi: 10.1016/j.sbi.2011.06.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Wadsten P, Wöhri AB, Snijder A, Katona G, Gardiner AT, Cogdell RJ, Neutze R, Engström S. Lipidic sponge phase crystallization of membrane proteins. J Mol Biol. 2006;364:44–53. doi: 10.1016/j.jmb.2006.06.043. [DOI] [PubMed] [Google Scholar]
- 23.Faham S, Bowie JU. Bicelle crystallization: a new method for crystallizing membrane proteins yields a monomeric bacteriorhodopsin structure. J Mol Biol. 2002;316:1–6. doi: 10.1006/jmbi.2001.5295. [DOI] [PubMed] [Google Scholar]
- 24.Newstead S, Hobbs J, Jordan D, Carpenter EP, Iwata S. Insights into outer membrane protein crystallization. Mol Membr Biol. 2008;25:631–638. doi: 10.1080/09687680802526574. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Trakhanov S, Quiocho F. Influence of divalent cations in protein crystallization. Protein Sci. 1995;4:1914–1919. doi: 10.1002/pro.5560040925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Newman J. Novel buffer systems for macromolecular crystallization. Acta Crystallogr D Biol Crystallogr. 2004;60:610–612. doi: 10.1107/S0907444903029640. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.